Navigation Links
Neurocrine Biosciences Reports First Quarter 2008 Results
Date:4/30/2008

mpact of 252 Fully Q3 08

period with elagolix elagolix on bone enrolled

and DMPA active mineral density

comparator plus using DXA scan

additional long-term 2. Dysmenorrhea and

safety assessments pelvic pain

post treatment

0702 Placebo-controlled Dysmenorrhea and 150 Enrolling 1H 09

trial with 2 doses pelvic pain

of optimized assessed with

formulation tablet modified endpoints

0703 Placebo-controlled Dysmenorrhea and 180 Initiated 1H 09

trial with 2 doses pelvic pain

of elagolix and assessed with

leuprolide depot modified endpoints

comparator

The Company completed enrollment in December 2007 of a Phase IIb study in which patients with endometriosis will be treated over a 6-month period. This multi-center, randomized, double-blind, study includes three treatment groups, with two doses of elagolix, 150 mg once a day and 75 mg twice daily, and an active comparator, Depo-Provera(R). In addition to confirming the effect of elagolix on endometriosis symptoms, this study is designed primarily to assess the impact of longer term treatment on bone mineral density as measured by DXA scan at the conclusion of dosing and at 6-months and 12-months post-treatment. Topline results from the 6-month treatment period are expected in the third quarter of 2008. The study will continue after the treatment period for DXA scans and safety assessments. The 6-month results, together with data from the other Phase II studies, will be the basis for securing agreement on a registration plan with the FDA.

The Company is also currently conducting two additional randomized placebo controlled Phase II clinical trials. The clinical endpoints for both of these trials are a reduction in pelvic pain associated wit
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
3. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
4. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
5. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
6. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
7. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
8. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
9. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
10. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
11. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , August 4, 2015 ... report with market overview, trends, DRO analysis, market ... developments, competitive scenario and top competitor profiles in: ... Testing Market Development and Demand Forecast to ... , Explore full reports with detailed ...
(Date:8/4/2015)... 2015 Organovo Holdings, Inc. (NYSE MKT: ... delivering scientific and medical breakthroughs using 3D bioprinting ... Paul Gallant as its General Manager ... business. Mr. Gallant has more than 20 years of ... industry, most recently serving as chief operating officer ...
(Date:8/4/2015)... , Aug. 04, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report ... in veterinary medicine and pharmaceuticals as well as ... is important in the application of biotechnology to ...
Breaking Medicine Technology:Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 3
... WIRE)--May 30, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB: ... a Phase I,trial of INNO-406, an orally ... or,treatment-intolerant chronic myelogenous leukemia, will be,presented at ... Annual,Meeting. The meeting takes place June 1- ...
... from various,clinical studies including a pivotal Phase III trial ... Nexavar (sorafenib) tablets will be presented at the Annual,Meeting ... USA from June 1 - 5, 2007. , On ... be held on June 4, 2007. Starting at around ...
Cached Medicine Technology:Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting 2
(Date:8/4/2015)... ... ... How cool is it to check in at your favorite place and ... will soon allow you to do just that. , Ahhaa is releasing the next ... feature. , Users will soon get to share what inspires them about their favorite ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... it has joined the American Association of Tissue Banks (AATB) as an Affiliate ... its mission “to honor donors, and to save and improve lives by promoting ...
(Date:8/4/2015)... FL (PRWEB) , ... August 04, 2015 , ... ... testing organization which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, announced their ... has been successfully identifying previously undiagnosed cardiovascular abnormalities one program at a time. ...
(Date:8/4/2015)... ... 2015 , ... Angelina Jolie is in it at age 39. “It” is ... Dr. Angela DeRosa, DO, MBA, CPE aka “Dr. Hot Flash,” arguably the Southwest’s ... of menopause. , Myth #1: Menopause only affects old ladies. – Menopause can ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... Food,” scheduled for Nov. 3 – 4, 2015, at UC San Diego, will ... new businesses, improve food access, and manage resources efficiently against the dueling backdrop ...
Breaking Medicine News(10 mins):Health News:Ahhaa App Soon to Release the "Now" Feature 2Health News:Exsurco Medical Joins AATB as Affiliate Member 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3
... by researchers at Columbia University,s Mailman School of Public ... children of a group of ubiquitous chemicals known as ... known to disrupt the endocrine system, and are widely ... household building materials, to shampoos. Recent studies of ...
... Psychogenic non-epileptic seizures may go undiagnosed for much longer in ... in the September 6, 2011, print issue of Neurology ... This type of seizure is different from seizures related to ... "People with psychogenic seizures are often diagnosed with epilepsy and ...
... in the Archives of General Psychiatry suggest that certain variants ... related to mood), may serve as a useful predictor of ... a trauma. "One of the critical questions surrounding ... the disorder following a trauma, while others appear to be ...
... Mann HealthDay Reporter , MONDAY, Sept. 5 ... are receiving their recommended vaccines, which could indicate that ... States. "We are getting better, but we still ... Rodewald, director of the immunization services division at the ...
... 5 (HealthDay News) - Rudeness among co-workers can have negative ... shows. Researchers from Baylor University found people who endure ... which can have negative effects on their family and marriages ... that when employees go home stressed and distracted, their partners ...
... , This press release is available in French ... by the European College of Neuropsychopharmacology (ECNP) sheds new light ... study finds reveal that mental disorders have become Europe,s largest ... that the majority of mental disorders remain untreated. Taken together ...
Cached Medicine News:Health News:Prenatal exposure to phthalates linked to decreased mental and motor development 2Health News:Non-epileptic seizures may be misdiagnosed longer in veterans 2Health News:The search for predictors of risk for PTSD 2Health News:More U.S. 'Tweens' Getting Recommended Vaccines 2Health News:More U.S. 'Tweens' Getting Recommended Vaccines 3Health News:Boorish Co-Workers Can Damage Your Home Life 2Health News:The size and burden of mental disorders in Europe 2Health News:The size and burden of mental disorders in Europe 3
Adson bipolar forceps, 12 cm, straight....
Bipolar foot activated forceps....
Olsen bayonet forceps, designed by Mr. Olsen in a configuration with 3 holes to make them lighter, more flexible, and also to ensure maximum grip for different procedures where there is limited acces...
Bayonet fine, smooth - 1/box....
Medicine Products: